•
Dec 31, 2024
PROCEPT BioRobotics Q4 2024 Earnings Report
PROCEPT BioRobotics reported strong revenue growth driven by increased system sales and consumables.
Key Takeaways
PROCEPT BioRobotics reported revenue of $68.2 million for Q4 2024, a 57% increase year-over-year. The company recorded a net loss of $18.9 million, improving from a loss of $27.5 million in the prior year period. Operating expenses increased due to commercial expansion and higher general and administrative costs. Gross margin improved to 64% from 49% in the prior year period.
Revenue increased 57% to $68.2 million.
Net loss narrowed to $18.9 million from $27.5 million.
Gross margin improved to 64% from 49%.
U.S. system revenue increased 67% year-over-year.
PROCEPT BioRobotics
PROCEPT BioRobotics
PROCEPT BioRobotics Revenue by Segment
PROCEPT BioRobotics Revenue by Geographic Location
Forward Guidance
PROCEPT BioRobotics projects strong revenue growth for 2025 driven by system placements and consumables.
Positive Outlook
- 2025 revenue projected to grow 42% to $320 million.
- Gross margin expected to improve to 64.5%.
- Continued expansion of commercial operations.
- Increased focus on global market penetration.
- Launch of new robotic platform to drive growth.
Challenges Ahead
- Projected adjusted EBITDA loss of $35 million for 2025.
- Higher operating expenses anticipated.
- Dependence on consumable sales for revenue growth.
- Potential impact from supply chain issues.
- Increased competition in the surgical robotics space.
Revenue & Expenses
Visualization of income flow from segment revenue to net income